OraPharma, Inc., Invites You to Participate in First Quarter 2001 Conference Call

Apr 23, 2001, 01:00 ET from OraPharma, Inc.

    WARMINSTER, Pa., April 23 /PRNewswire Interactive News Release/ --
 OraPharma, Inc. (Nasdaq: OPHM) will issue its first quarter earnings
 announcement on April 26, 2001.  There will also be a Conference Call, hosted
 by Michael Kishbauch, President and CEO, and Jim Ratigan, CFO, to review the
 matters discussed in the press release.  OraPharma would like you to
 participate in the Conference Call.
 
                           Thursday, April 26, 2001,
                      at 11:30 a.m. Eastern Daylight Time
 
                          To participate in this call,
                        dial: 888-216-6046 (U.S./Canada)
                          706-634-0098 (International)
                shortly before 11:30 a.m. Eastern Daylight Time
 
     A replay of the call will be available from 2:30 p.m. EDT, Thursday,
 April 26, until 12:00 a.m. EDT Wednesday, May 2, 2001.  The replay can be
 accessed by dialing 800-642-1687 (U.S./Canada) or 706-645-9291
 (International), followed by entering ID number 819895.
     Please contact Adam Saia, Cohn & Wolfe, at 212-798-9758, to confirm your
 participation.
 
     OraPharma, Inc., a specialty pharmaceutical company, discovers, develops,
 and commercializes therapeutics for oral health. The Company's other
 technological initiatives, which are in the preclinical stage of development,
 include a compound for the treatment of oral mucositis, a complication of
 cancer therapy, and an agent for bone and tissue regeneration. During 2001,
 the Company will seek approval from the FDA to begin human clinical trials for
 both the oral mucositis and bone regeneration products. In addition, the
 Company has two early stage product development projects, including a
 next-generation periodontal therapeutic, and a dental trauma preparation.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X30976426
 
 

SOURCE OraPharma, Inc.
    WARMINSTER, Pa., April 23 /PRNewswire Interactive News Release/ --
 OraPharma, Inc. (Nasdaq: OPHM) will issue its first quarter earnings
 announcement on April 26, 2001.  There will also be a Conference Call, hosted
 by Michael Kishbauch, President and CEO, and Jim Ratigan, CFO, to review the
 matters discussed in the press release.  OraPharma would like you to
 participate in the Conference Call.
 
                           Thursday, April 26, 2001,
                      at 11:30 a.m. Eastern Daylight Time
 
                          To participate in this call,
                        dial: 888-216-6046 (U.S./Canada)
                          706-634-0098 (International)
                shortly before 11:30 a.m. Eastern Daylight Time
 
     A replay of the call will be available from 2:30 p.m. EDT, Thursday,
 April 26, until 12:00 a.m. EDT Wednesday, May 2, 2001.  The replay can be
 accessed by dialing 800-642-1687 (U.S./Canada) or 706-645-9291
 (International), followed by entering ID number 819895.
     Please contact Adam Saia, Cohn & Wolfe, at 212-798-9758, to confirm your
 participation.
 
     OraPharma, Inc., a specialty pharmaceutical company, discovers, develops,
 and commercializes therapeutics for oral health. The Company's other
 technological initiatives, which are in the preclinical stage of development,
 include a compound for the treatment of oral mucositis, a complication of
 cancer therapy, and an agent for bone and tissue regeneration. During 2001,
 the Company will seek approval from the FDA to begin human clinical trials for
 both the oral mucositis and bone regeneration products. In addition, the
 Company has two early stage product development projects, including a
 next-generation periodontal therapeutic, and a dental trauma preparation.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X30976426
 
 SOURCE  OraPharma, Inc.